Across TCGA pan-cancer cohorts, HLA-DOA mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HLA-DOA data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher HLA-DOA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HLA-DOA expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD and LSCC are the cancer types where HLA-DOA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	1.000	0.441	.005	13	view →
LSCC	DFS	Median	II,III,IV	0.864	0.974	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: HLA-DOA tumor-vs-normal RNA expression · all HLA-DOA data types